Director awarded 20,000 options at $0.54 at Pharma-Bio Serv (PBSV)

Rhea-AI Filing Summary

Pharma-Bio Serv, Inc. reported a routine insider equity award for director Dov Perlysky. On January 10, 2026, he was granted a stock option covering 20,000 shares of common stock at an exercise price of $0.54 per share. The option vests in two equal installments on July 10, 2026 and July 10, 2027, and expires on January 10, 2031. Following this grant, Perlysky beneficially owns 20,000 derivative securities directly in the form of this option.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Perlysky Dov

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	20,000	$0.00	--

Holdings After Transaction: Stock Option — 20,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Perlysky Dov

(Last) (First) (Middle)

2 LAKESIDE DRIVE WEST

(Street)

LAWRENCE NY 11559

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pharma-Bio Serv, Inc. [ PBSV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.54	01/10/2026		A		20,000		(1)	01/10/2031	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. The option vests in two equal installments on July 10, 2026 and July 10, 2027.

	/s/ Dov Perlysky	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pharma-Bio Serv (PBSV) report on this Form 4?

The filing reports that director Dov Perlysky received a grant of a stock option on January 10, 2026, covering shares of Pharma-Bio Serv, Inc. common stock.

How many Pharma-Bio Serv (PBSV) shares are covered by the new stock option grant?

The stock option grant covers 20,000 shares of Pharma-Bio Serv, Inc. common stock, all reported as beneficially owned following the transaction.

What is the exercise price and term of the Pharma-Bio Serv (PBSV) stock option granted to Dov Perlysky?

The option has an exercise price of $0.54 per share and an expiration date of January 10, 2031, giving the director the right to buy shares at that price until expiration.

When do the stock options granted to the Pharma-Bio Serv (PBSV) director vest?

According to the footnote, the option vests in two equal installments on July 10, 2026 and July 10, 2027, meaning half becomes exercisable on each of those dates.

What is Dov Perlysky’s relationship to Pharma-Bio Serv (PBSV)?

Dov Perlysky is reported as a director of Pharma-Bio Serv, Inc., and the Form 4 indicates that this stock option is held under direct ownership.

How many derivative securities does the Pharma-Bio Serv (PBSV) director own after this Form 4 transaction?

Following the option grant, Dov Perlysky beneficially owns 20,000 derivative securities, all represented by this stock option award.